Literature DB >> 16609157

Genotype distribution amongst hepatitis C patients in The Netherlands.

M J de Vries1, B te Rijdt, C M J van Nieuwkerk.   

Abstract

BACKGROUND: The prevalence of the genotypes of the hepatitis C virus (HCV) differs according to geographical location. In the United States and in European countries, the majority of patients are infected with genotype 1, 2 or 3. There is a lack of data on the distribution of HCV genotypes in The Netherlands.
METHODS: The current survey determined the distribution of HCV genotypes amongst recently genotyped patients seen by physicians treating hepatitis C in The Netherlands.
RESULTS: Almost half of the 351 patients (49.3%) were infected with genotype 1. Genotype 3 was the second most dominant genotype with a prevalence of 29.3%. Genotypes 2 and 4 were found in 9.7 and 10.5% of the patients, respectively. For 61.5% of the patients (n=216), the subtype was available. For genotype 1 the prevalence of subtype 1a and 1b was very similar, while for genotype 3 a large majority of patients were infected with subtype 3a.
CONCLUSION: This survey gives the first estimation of the distribution of HCV genotypes amongst unselected HCV patients in The Netherlands.

Entities:  

Mesh:

Year:  2006        PMID: 16609157

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  7 in total

1.  Cellular immune response to infection by different genotypes of hepatitis C virus.

Authors:  Mohamed El-Shahat Ebeid; Kadry Abdel-Kader El-Bakry
Journal:  Indian J Clin Biochem       Date:  2009-09-16

Review 2.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

Authors:  Francois Roman; Karin Hawotte; Daniel Struck; Anne-Marie Ternes; Jean-Yves Servais; Vic Arendt; Patrick Hoffman; Robert Hemmer; Therese Staub; Carole Seguin-Devaux; Jean-Claude Schmit
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

4.  Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles.

Authors:  Joep de Bruijne; Janke Schinkel; Maria Prins; Sylvie M Koekkoek; Sem J Aronson; Marijn W van Ballegooijen; Hendrik W Reesink; Richard Molenkamp; Thijs J W van de Laar
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

5.  The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey.

Authors:  Derya Keten; Mehmet Emin Ova; Hamit Sirri Keten; Alper Keten; Evrim Gulderen; Seray Tumer; Ahmet Caliskan; Suleyman Kulotu
Journal:  Jundishapur J Microbiol       Date:  2016-02-13       Impact factor: 0.747

6.  Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Authors:  Vincent Leroy; Peter Angus; Jean-Pierre Bronowicki; Gregory J Dore; Christophe Hezode; Stephen Pianko; Stanislas Pol; Katherine Stuart; Edmund Tse; Fiona McPhee; Rafia Bhore; Maria Jesus Jimenez-Exposito; Alexander J Thompson
Journal:  Hepatology       Date:  2016-03-04       Impact factor: 17.425

7.  Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study.

Authors:  Cas J Isfordink; Thijs J W van de Laar; Sjoerd P H Rebers; Els Wessels; Richard Molenkamp; Marjolein Knoester; Bert C Baak; Cees van Nieuwkoop; Bart van Hoek; Sylvia M Brakenhoff; Hans Blokzijl; Joop E Arends; Marc van der Valk; Janke Schinkel
Journal:  Open Forum Infect Dis       Date:  2021-01-06       Impact factor: 3.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.